Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Bladder cancer; Urethral cancer
- Focus Therapeutic Use
- 09 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
- 09 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2018.
- 09 Aug 2017 Status changed from active, no longer recruiting to recruiting.